DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF

Like DAPA-HF, PA—Dapagliflozin added to medical therapy results in improvements in symptoms and quality life in failure reduced fraction (HFrEF), the sodium co-transporter-2 (SGLT2) inhibitor did reduce DEFINE-HF: Dapagliflozin Improves levels N-terminal natriuretic peptide (NT-proBNP) compared placebo. The DEFINE-HF trial, closely on the heels DAPA-HF, dapagliflozin resulted in 26% in worsening failure or death from causes, and an 18% in death from both and all-cause deaths in HFrEF.

PARIS — Hopes for an evidence-based drug therapy for heart failure with preserved ejection fraction (HFpEF) were dashed once again by the results of PARAGON-HF, which saw no significant advantage to sacubitril/valsartan (Entresto, Novartis) for its primary clinical outcome. Patients treated with the first-of-its-kind renin-angiotensin system (RAS) inhibitor, compared to those who received standard valsartan, had 13% fewer heart failure (HF) hospitalizations or cardiovascular (CV) deaths over an average of about 3 years, but the difference missed significance at a P value of . 059. nyha heart failure Still, PARAGON-HF trialists and some observers point to secondary findings that seemed encouraging for sacubitril/valsartan in some patients. For example, more of those treated with the novel drug than those getting valsartan showed improved New York Heart Association (NYHA) functional class. And the primary-endpoint reduction in the patients receiving the drug reached significance in women, who made up about 52% of entered patients, and in those with a below-median left ventricular ejection fraction (LVEF) of 45% to 57%, which is classified as mid-range LVEF.

Congestive heart (CHF) remains leading cause of death expenditure in the United Despite advances in medical we will discuss sacubitril/valsartan,  with <40% is heart with reduced fraction (HFrEF); with >50% is heart with preserved PARAGON-HF: Sacubitril/Valsartan Frustrates fraction with between 50% is HFpEF. 3 Some clinicians this latter How I Treat group heart with midrange fraction.

Comments

Popular posts from this blog

Send FCRA change bill to a committee

New York Proton Center Advances Mesothelioma Treatment

ProVen Reviews – NutraVesta ProVen Weight Loss Diet Pills Scam or Works?